Literature DB >> 29025714

Racial/ethnic disparities: need more work!

Ola Landgren1.   

Abstract

Mesh:

Year:  2017        PMID: 29025714      PMCID: PMC5639487          DOI: 10.1182/blood-2017-08-798546

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

Review 1.  Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis.

Authors:  O Landgren; B M Weiss
Journal:  Leukemia       Date:  2009-07-09       Impact factor: 11.528

2.  Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity.

Authors:  Luciano J Costa; Parameswaran N Hari; Shaji K Kumar
Journal:  Leuk Lymphoma       Date:  2016-04-22

Review 3.  Racial and ethnic disparities in hematologic malignancies.

Authors:  Kedar Kirtane; Stephanie J Lee
Journal:  Blood       Date:  2017-07-19       Impact factor: 22.113

4.  Understanding disparities in leukemia: a national study.

Authors:  M I Patel; Y Ma; B S Mitchell; K F Rhoads
Journal:  Cancer Causes Control       Date:  2012-09-13       Impact factor: 2.506

5.  Effects of poverty and race on outcomes in acute myeloid leukemia.

Authors:  Margaret M Byrne; L Jill Halman; Leonidas G Koniaris; Peter A Cassileth; Joseph D Rosenblatt; Michael C Cheung
Journal:  Am J Clin Oncol       Date:  2011-06       Impact factor: 2.339

6.  Racial disparities in incidence and outcome in multiple myeloma: a population-based study.

Authors:  Adam J Waxman; Pamela J Mink; Susan S Devesa; William F Anderson; Brendan M Weiss; Sigurdur Y Kristinsson; Katherine A McGlynn; Ola Landgren
Journal:  Blood       Date:  2010-09-07       Impact factor: 22.113

7.  Age and genetics: how do prognostic factors at diagnosis explain disparities in acute myeloid leukemia?

Authors:  Manali I Patel; Yifei Ma; Beverly S Mitchell; Kim F Rhoads
Journal:  Am J Clin Oncol       Date:  2015-04       Impact factor: 2.339

8.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.